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Pioneer factors are proteins that can recognize their target sites in barely accessible
chromatin and initiate a cascade of events that allows for later transcriptional activation
of the respective genes. Pioneer factors are therefore particularly well-suited to initiate cell
fate changes. To date, only a small number of pioneer factors have been identified and
studied in depth, such as FOXD3/FOXA1, OCT4, or SOX2. Interestingly, several recent
studies reported that the PBC transcription factor PBX1 can access transcriptionally
inactive genomic loci. Here, we summarize the evidence linking PBX1 with transcriptional
pioneer functions, suggest potential mechanisms involved and discuss open questions
to be resolved.
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TRANSCRIPTIONAL PIONEER FACTORS
Transcriptional activation or repression of tissue specific genes is typically controlled by a set of
sequence specific transcription factors (TFs), together with additional co-regulatory proteins. In
addition, there is accumulating evidence that efficient de novo activation of previously silent genes
often also depends on DNA–protein interactions and chromatin modifications that occur long
before mRNA transcripts of these genes can be detected. These processes are carried out by a
special type of DNA binding proteins, termed pioneer TFs (Smale, 2010; Iwafuchi-Doi and Zaret,
2014). Two of the first identified and best studied pioneer factors are the FOX family members
FOXD3 and FOXA1. FOXD3 is bound to an enhancer of the liver specific albumin (Alb1) gene
already in embryonic stem cells (ESCs), although the gene is not transcriptionally activated until
hepatocyte differentiation (Gualdi et al., 1996; Bossard and Zaret, 1998; Xu et al., 2007). During
endodermal differentiation, FOXD3 gets downregulated and FOXA1 becomes upregulated and
subsequently binds this Alb1 enhancer together with GATA-4 (Gualdi et al., 1996; Bossard and
Zaret, 1998). FOXD3 thus serves as a placeholder for FOXA1 and both proteins provide an early
molecular anchor for other TFs at the Alb1 enhancer, facilitating later Alb1 gene activation upon
differentiation into hepatocytes (Smale, 2010).
Since the 1990s, a number of additional pioneer TFs were discovered. The emerging definition
of a pioneer factor comprises the ability to (1) engage its target site(s) in closed chromatin prior to
gene activation, (2) increase chromatin accessibility for other proteins at this site, and (3) establish
competence for cell fate changes and thus play a key role in cellular (re-) programming (Iwafuchi-
Doi and Zaret, 2014). For about two decades, the pressing question of how pioneer factors can
access genomic sites in silent chromatin remained a largely unresolved issue, yet recent structural
investigations from the Zaret laboratory provide novel advances in the understanding of possible
binding modes of pioneer factors to nucleosomal DNA (Soufi et al., 2015). Previously, it was
postulated that pioneer factors may access their binding sites in compacted chromatin because of
a local destabilization of the nucleosome-DNA contact. Suggested mechanisms of destabilization
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were the presence of poly(dA-dT) sequences or of histone
variants such as H3.3 or H2A.Z (Sekinger et al., 2005; Zhang
et al., 2005; Jin et al., 2009). However, genome-wide approaches
found that many regulatory regions do not coincide with DNA
sequences that assemble into unstable nucleosomes (Zaret and
Carroll, 2011). Instead, there is accumulating evidence that
pioneer TFs can recognize their target DNA binding sites even
in compacted chromatin. The prototype pioneer factor FOXA1,
for instance, associates with DNA through a “winged helix”-
type DNA binding domain, which structurally resembles the
linker histones H1 and H5 (Clark et al., 1993; Ramakrishnan
et al., 1993). The FOXA1 C-terminus, on the other hand, can
bind to core histones independently of the protein’s DNA-
binding domain (Cirillo et al., 2002; Sekiya et al., 2009).
These structural characteristics enable FOXA1 to penetrate
nucleosomal chromatin and, by competition, to displace linker
histones. FOXA1 thereby paves the way for other TFs to
bind. Consequently, pioneer factors, like linker histones, are
retained on mitotic chromosomes and thus might assume a
“bookmarking” function during mitosis (Yan et al., 2006; Taube
et al., 2010; Zaret et al., 2010; Iwafuchi-Doi et al., 2016).
However, not all known pioneer factors possess such linker
histone-like properties or winged helix motifs. For example, the
reprogramming factors OCT4, SOX2, and KLF4 share the ability
to target partial recognition motives on nucleosomes where only
one face of the DNA is accessible, yet possess very different
DNA binding domains. In addition, recent studies suggest that
occupancy of enhancer regions by nucleosomes may actually
favor pioneer factor binding and thereby mediate cooperativity
between factors that would not necessarily interact on naked
DNA (Iwafuchi-Doi and Zaret, 2014; Iwafuchi-Doi et al., 2016).
But what if the nucleosome units are inaccessible, hidden
in tight heterochromatin? For a number of pioneer TFs special
chromatin binding properties have been reported. An example
is the sequence-independent affinity of some bona-fide pioneer
TFs to histone modifications, such as mono- or di-methylation
of lysine 4 on histone 3 (H3K4me1 or H3K4me2), epigenetic
modifications that occur on active enhancers (Cirillo et al., 2002;
Sekiya et al., 2009; Magnani et al., 2011). The current view is that
this initial, global recruitment to chromatin enables the pioneer
TFs to scan the surrounding sequences for their recognition
motives (Soufi et al., 2015). Other heterochromatin regions, like
those where H3K9me2 or H3K9me3 marks are deposited, remain
inaccessible even to pioneer factors (Soufi et al., 2012; Iwafuchi-
Doi and Zaret, 2014). Collectively, these studies have begun
to shed light onto the versatile mechanisms used by pioneer
factors to engage their target sites in closed chromatin (Table 1).
However, the sequence of events during initial heterochromatin
opening, involving chromatin modifications, pioneer factors,
and possibly additional components, are still subject of debate
(Choukrallah and Matthias, 2014). In addition, mechanistic
details are only known for a small number of pioneer factors at
present. Given the enormous complexity of cell lineage decisions
during embryonic development and the recent advancements to
revert these decisions by cellular reprogramming strategies, many
more TFs with pioneering activity may wait to be discovered.
PBC PROTEINS IN DEVELOPMENT, ADULT
STEM CELLS, AND CANCER
Pre-B cell leukemia (PBC) TFs are evolutionarily conserved,
atypical homeodomain proteins. Phylogenetically, they
constitute one class of the Three Amino acid Loop Extension-
homeodomain (TALE-HD) superclass, a separate branch of the
homeodomain proteins characterized by the name-giving Three
Amino acid Loop Extension (“TALE”) between the first and
second alpha-helix of the homeodomain (Gehring et al., 1994;
Bürglin and Affolter, 2016). In animals, TALE-HD proteins
can be subdivided into five classes (PBC, MEIS, IRO, MKX,
TGIF), of which the PBC-class, consisting of pre-B cell leukemic
homeobox (PBX) 1–4 proteins in mammals, will be addressed in
more detail here.
PBC proteins were originally identified as HOX-cofactors
in D. melanogaster, because mutants of the fly PBC protein
extradenticle displayed homeotic transformations similar to those
seen in Hox-mutant animals, without altering the expression
of the respective Hox genes themselves (Peifer and Wieschaus,
1990; Rauskolb et al., 1993, 1995). Subsequent studies revealed
that this protein class contributes to the correct patterning of
the anterior–posterior and proximal–distal body axes, confers
regional identity in the embryo and is involved in the
regulation of proliferation, apoptosis, and differentiation during
embryogenesis (Berkes et al., 2004; Ferretti et al., 2011; Gordon
et al., 2011; Koss et al., 2012; Yao et al., 2013). For instance,
knockout of Pbx1 in mouse embryos leads to embryonic lethality
at E15/E16 with hypoplasia or aplasia of several organs, including
impaired hematopoiesis, incomplete development of the thymus,
spleen agenesis, pancreas hypoplasia, second branchial arch
transformation, malformations of cervical vertebrae, ribs, and
proximal limbs, and failure of septation of the cardiac outflow
tract (DiMartino et al., 2001; Selleri et al., 2001; Manley et al.,
2004; Brendolan et al., 2005; Stankunas et al., 2008). The unifying
concept emerging from these studies is that PBX proteins act at
or near the top of multiple cell fate hierarchies.
Corroborating their multifaceted roles during embryogenesis,
dysregulation of PBC proteins is also a frequent phenomenon in
cancer. In fact, the mammalian PBX1 protein was first identified
in a chromosomal translocation [t(1;19) (q23;p13.3)] in pre-B
cell acute lymphoblastic leukemia (ALL) that resulted in the
expression of an oncogenic E2A-PBX1 fusion protein (Carroll
et al., 1984; Williams et al., 1984; Kamps et al., 1990, 1991).
Oncogenic roles of HOX/PBX dimers have also been reported
in many other cancers and can be blocked by peptide-based
inhibition (Morgan et al., 2007, 2010; Ando et al., 2014; Kelly
et al., 2016). In addition, PBX1 plays an important role in
estrogen receptor alpha (ERα)-positive breast carcinogenesis
(Magnani et al., 2011). In contrast to their rather well-studied
roles in embryonic development and cancerousmalignancies, the
contribution of PBC proteins to adult stem cell niches is still
largely unexplored. In the hematopoietic system, PBX1 regulates
long term hematopoietic stem cell quiescence, limits myeloid
maturation and preserves a lymphoid potential in multipotent
progenitor (MPP) and common myeloid progenitor (CMP)
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TABLE 1 | Overview over pioneering mechanisms.
Pioneer factor Cellular context of pioneering Proposed pioneering mechanism References
Ascl1 - Direct lineage conversion from fibroblasts or other
somatic cells to neurons
- Neuronal differentiation from ESCs
Nucleosomal targets contain an extra “G”
nucleotide at the 3′-end of the E
- Box motif
Vierbuchen et al., 2010; Karow et al.,
2012; Wapinski et al., 2013; Yamamizu
et al., 2013; Raposo et al., 2015; Soufi
et al., 2015
FoxD3 - Hepatocyte initial specification,
- Binding to the Alb1 enhancer in ESCs
Winged helix DBD Clark et al., 1993; Ramakrishnan et al.,
1993; Gualdi et al., 1996; Bossard and
Zaret, 1998; Xu et al., 2007, 2009
FoxA1/A2 - Hepatocyte later specification and differentiation,
replacement of FoxD3 at the Alb1 enhancer in definite
endoderm;
- Breast cancer (regulation of the estrogen response)
- Winged helix DBD;
- Favors “accessible nucleosomes”
- Genome scanning
- H3K4me1/H3K4me2 binding
Xu et al., 2007; Magnani et al., 2011;
Magnani and Lupien, 2014; Iwafuchi-Doi
et al., 2016
Klf4 - iPSC reprogramming,
- Different types of cancer
- Cell lineage specification in the embryo
- Targeting of a degenerate hexameric motif
(instead of canonical nonameric motif) at
nucleosome-enriched sites
Takahashi and Yamanaka, 2006; Soufi
et al., 2012, 2015
Oct4 - iPSC reprogramming,
- Several types of cancer
- Involved in the development of different cell lineages
during embryogenesis
- Binding of separate half sites of the bipartite
POU-domain (POUS/POUHD)
Takahashi and Yamanaka, 2006; Soufi
et al., 2012, 2015
PU.1 - Hematopoietic lineages Unknown Smale, 2010; Barozzi et al., 2014
Sox2 - iPSC reprogramming
- Neuronal fate specification
Recognition of a degenerate motif facilitating
recognition of histone bound DNA minor groove
Takahashi and Yamanaka, 2006; Karow
et al., 2012, 2014; Soufi et al., 2015
Pbx1 - Skeletal muscle lineage specification;
- Breast cancer (regulation of the estrogen response);
- Adult neurogenesis and neuronal lineage specification
- H3K4me1/H3K4me2 binding Berkes et al., 2004; Maves et al., 2007;
Magnani et al., 2011; Thiaville et al.,
2012; Grebbin et al., 2016
Summarizes several established pioneer factors in comparison to PBX1. The list gives the physiological contexts in which priming was established and potential mechanisms that may
mediate their priming function. For more detailed information on these proteins or for further discussion of general priming and pioneer factor mechanisms we would like to refer the
reader to a series of excellent recent reviews (Iwafuchi-Doi and Zaret, 2014; Magnani and Lupien, 2014; Zaret and Mango, 2016).
pools, thereby regulating and maintaining progenitor reservoirs
(Ficara et al., 2013).
The subventricular zone (SVZ) in rodents is an adult stem cell
niche that provides new neurons and glia to the brain. In brief,
adult stem cells residing in the SVZ produce young neurons,
termed neuroblasts, via an intermediate population of transient
amplifying progenitor cells. Neuroblasts leave the SVZ and
migrate into the olfactory bulb where they terminally differentiate
to distinct types of interneurons that are continuously replaced
in the existing circuitry as part of a life-long remodeling of
the olfactory system. A number of TFs, including DLX2 and
PAX6, bias progenitor cells toward a general neuronal fate
and promote their subsequent maturation to defined types
of interneurons (Hack et al., 2005; Brill et al., 2008). In
cooperation with PAX6 and DLX2, the TALE-HD protein MEIS2
regulates neuronal cell fate acquisition, as well as the terminal
differentiation of neuroblasts into dopaminergic periglomerular
neurons (Agoston et al., 2014). Recently, we characterized the
contribution of PBX1 to adult SVZ neurogenesis (Grebbin
et al., 2016). We observed high PBX1 expression in rapidly
proliferating SVZ progenitors and neuroblasts, as well as in
subsets of their progenies in the olfactory bulb, including
dopaminergic neurons. Targeted deletion of Pbx1 in transient
amplifying progenitor cells (in a Pbx2-deficient background to
prevent functional compensation by this structurally related
gene) significantly reduced the production of neurons and
increased the generation of oligodendrocytes in vitro and in
vivo, establishing Pbx1 as an early lineage regulator of SVZ
neurogenesis. Loss of Pbx1 expression in neuronally committed
neuroblasts, by contrast, severely compromised cell survival.
By chromatin immunoprecipitation from endogenous tissues or
isolated cells, we identified the neuron-specific gene doublecortin
(Dcx) and the dopaminergic neuron marker gene tyrosine
hydroxylase (Th), as direct PBX1 target genes.
Notably, PBX1 binds to its target sites in promoter/enhancer
regions of these genes already in undifferentiated progenitor cells
and hence at times that significantly precede the transcriptional
activation of both genes. The Dcx gene encodes a microtubule-
associated protein, which is expressed by all migrating
neuroblasts and therefore a frequently used marker for young
neurons (Francis et al., 1999; Gleeson et al., 1999). Primary
cultures of proliferating adult SVZ neural stem- and progenitor
cells (neurospheres) are DCX negative, but the protein becomes
quickly upregulated once differentiation is induced. Although
undifferentiated neurospheres do not yet express DCX and the
Dcx locus exhibits very low levels of the activating epigenetic
histone modification H3K4me3, a significant enrichment of
PBX1 at the Dcx promoter was observed, indicating that PBX
chromatin binding preceded Dcx gene activation. In contrast
to the relatively fast upregulation of pan-neuronal markers like
Dcx, terminal differentiation and integration of adult generated
neurons into the existing circuitry of the olfactory bulb represent
the last steps of neuronal turnover during adult neurogenesis.
Full maturation of dopaminergic neurons is a particularly slow
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process and ∼2 months pass before an adult SVZ-generated
neuron reaches the olfactory bulb and achieves a level of cellular
maturation at which Th expression is initiated (Brill et al.,
2008). Unexpectedly, PBX1 occupies the Th promoter/proximal
enhancer already in progenitor cells and newborn neuroblasts
in the SVZ, suggesting that priming by PBX1 can precede
transcriptional activation of the Th gene by several months.
PBX PIONEERING?
Our observation that PBX1 may bind its targets in silent gene
loci does not stand alone. In fact, the first evidence for a
pioneering role of PBX1 was provided by Berkes et al. (2004).
The authors observed that during skeletal muscle differentiation
PBX1 is constitutively bound to the promoter of the Myogenin
gene. Differentiation and activation of Myogenin expression are
subsequently initiated by the pro-myogenic transcription factor
MYOD through interaction with pre-bound PBX1. At the onset
of myogenic differentiation, PBX1 thus seems to serve as a
platform for MYOD binding in inactive chromatin, thereby
preparing genes of the skeletal muscle lineage for activation
(Berkes et al., 2004; Maves et al., 2007). This finding was
supported in 2011 by a report describing PBX1 as a pioneer
factor in ERα-signaling in breast cancer (Magnani et al., 2011).
Using the cell line MCF7 as model to investigate the activation
of oncogenic ERα target genes during breast cancer progression,
the study identified PBX1 as “partner” pioneer factor to FOXA1.
PBX1 is pre-bound to shared PBX1-ERα binding sites proximal
to genes involved in cancer cell proliferation prior to estrogen
application and its binding to these sites remains following
estrogen treatment. Although FOXA1 and PBX1 pioneering
functions are independent from each other, the presence of
both factors has a synergistic effect on chromatin openness on
shared binding sites (Magnani et al., 2011). Together, PBX1 pre-
loading to chromatin before estrogen treatment and its ability to
induce chromatin opening argue for a pioneering function in this
context.
In contrast to FOXA1, little is known about the mechanisms
that may allow PBX1 to access silent chromatin. However, the
detailed structural analysis of the iPSC reprogramming factors
Oct4, Sox2, Klf4, and c-Myc may provide a hint. Specifically,
the length of the basic helix-loop-helix domain of bHLH
proteins appears to inversely correlate with pioneer activity, as
short bHLH basic regions facilitate nucleosomal DNA binding,
whereas proteins with longer bHLH basic regions depend on the
cooperation with other pioneer factors (Nair and Burley, 2003;
Sauvé et al., 2004; Soufi et al., 2015). The ability of a bHLH
protein to access closed chromatin thereby appears to be either
defined by the way helix 1 contacts DNA or by cooperation
with additional factors, leading to recognition of target sequences
which may contain partial, degenerate or altered motifs (Soufi
et al., 2015). In this context it is intriguing to consider that the
TALE-homeodomain, owing to the insertion of three amino acids
between helix 1 and helix 2, is structurally distinct from other
homeodomains (Gehring et al., 1994; Bürglin and Affolter, 2016).
This raises the possibility that the TALE-HD might be especially
suited to recognize its consensus motif on nucleosomal DNA, but
to date mechanistic details remain unknown.
An alternative scenario was described by Magnani et al. who
reported that PBX1, as had been previously shown for FOXA1,
preferably associates with nucleosomes carrying H3K4me1 and
H3K4me2 modifications (Magnani et al., 2011; Sérandour et al.,
2011; Jozwik et al., 2016). Mono- and di-methylation of
H3K4 mark distal enhancers that are linked to active or
poised genes and can be found as biochemical intermediates
preceding the triple-methylation of H3K4 at transcriptionally
active promoters. As H3K4me1 deposition is catalyzed by
the Set/MLL family proteins MLL3 and MLL4, this would
paradoxically suggest that FOXA1 and PBX1 binding to DNA
requires prior histone modification by MLL3/4, a notion that
is difficult to reconcile with the proven or proposed pioneering
activity of FOXA1 and PBX1, respectively (Hu et al., 2013).
A possible explanation comes from the observation that the
relationship between pioneer factor binding andH3K4 epigenetic
modification seems to be bidirectional: The pioneer factors
FOXA1 and PU.1 not only preferentially bind to chromatin
carrying H3K4me1/H3K4me2 modifications, but their association
in turn promotes H3K4me1/2 deposition (Heinz et al., 2010;
Sérandour et al., 2011). The essential question of which is
present on the chromatin first, the nucleosomal modification
or the pioneer factor, cannot be conclusively answered. At
present, examples for both cases exist and quite possibly,
pioneer factor binding and epigenetic histone modifications
stabilize each other. Moreover, unknown additional players
might be involved, such as long or short non-coding RNAs. In
any respect, further efforts are needed to decipher the whole
spectrum of mechanisms used by pioneer factors to access closed
chromatin.
In conclusion, multiple lines of evidence, obtained from
in vivo and in vitro studies and made in the context of
embryonic development, adult stem cell differentiation and
cancer, suggest that PBX1 may act as pioneer factor. The
three hallmarks of pioneer factor function—target site binding
in closed chromatin, the ability to increase DNA access for
other proteins and active involvement in cell fate specification
or cellular (re-)programming—have all been demonstrated for
PBX1. Yet, each of these features has been investigated in a
different physiological setting and with different tools. A unifying
model is therefore still missing. In addition, little is known
about whether the other three members of the mammalian
PBC family, PBX2-4, also possess the ability to recognize their
target sites in silent chromatin or even pioneer factor activity. A
coherent assessment of PBX pioneering function by standardized
approaches is therefore an important next step in research on this
protein family.
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